[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

North America Radioactive Tracer Market Forecast to 2030 - Regional Analysis - by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others), and End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, and Others)

December 2023 | 112 pages | ID: N74AFA93A065EN
The Insight Partners

US$ 3,550.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
The North America radioactive tracer market was valued at US$ 8,139.16 million in 2022 and is expected to reach US$ 29,331.01 million by 2030; it is estimated to grow at a CAGR of 17.4% from 2022 to 2030.

Increasing Use of Nuclear Imaging Techniques fuel the North America Hair Extension Market

PET and SPECT are among the nuclear medicine radiology modalities employed in clinical settings. Their use is increasing as they offer accurate detection, localization, and characterization of diseases. Ionizing radiation for diagnosis and treatment benefits millions of patients globally. Radiation in medicine helps earlier diagnosis and often offers less invasive treatments for human diseases. Advanced radiation technology has opened new horizons in diagnostic and nuclear medicine, radiotherapy, and interventional radiology. According to World Health Organization, over 3,600 million diagnostic radiology examinations are performed, 37 million nuclear medicine procedures are carried out, and 7.5 million radiotherapy treatments are given annually. The development and introduction of new radiopharmaceuticals for PET/CT and SPECT/CT procedures, which are used in novel clinical applications such as neurology and orthopedics, and the growing accuracy of different tumor staging methods contribute to the growth of the radioactive tracer market. For instance, newly introduced cardiac radiopharmaceuticals such as flurpiridaz F-18 and ammonia N-13 help in more precise imaging of cardiovascular conditions. Thus, constant technological advancements for improving the quality and efficacy of nuclear imaging techniques favor the growth of the radioactive tracer market.

North America Radioactive Tracer Market Overview

The North America radioactive tracer market is segmented into the US, Canada, and Mexico. In 2022, the US held the largest share of the North America radioactive tracer market. Rising number of patients suffering from chronic conditions and viral diseases, increasing activities in research and development in advanced diagnosis method are the key factors propelling the market for radioactive tracer. Also, the increasing use of nuclear imaging techniques are favoring market expansion.

North America Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Million)

North America Radioactive Tracer Market Segmentation

The North America radioactive tracer market is segmented based on tracer type, test type, end user, application, and country. Based on tracer type, the North America radioactive tracer market is segmented into technetium-99m & Tc-97m, iodine-131, iron-59, lutetium-171, rubidium (Rb-82) chloride & ammonia (N-13), scandium-46, seaborgium-269, hassium-269, Gallium citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), phosphorus-32 & chromium-51, thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and others. The others segment held the largest market share in 2022.

Based on test type, the North America radioactive tracer market is segmented into PET, SPECT, and others. The SPECT segment held the largest market share in 2022.

Based on end user, the North America radioactive tracer market is segmented into hospitals & clinics, diagnostic centers, academic & research institutes, and others. The hospitals & clinics segment held the largest market share in 2022.

Based on application, the North America radioactive tracer market is segmented into oncology, pulmonary, neurology, cardiology, and others. The oncology segment held the largest market share in 2022.

Based on country, the North America radioactive tracer market is segmented into the US, Canada, and Mexico. The US dominated the North America radioactive tracer market share in 2022.

Rotem Industries Ltd, Invicro LLC, Cardinal Health Inc, Newcastle University, Novartis AG, Curium, Blue Earth Diagnostics Limited, General Electric Co, and IBA Radiopharma Solutions are some of the leading players operating in the North America radioactive tracer market.
1. INTRODUCTION

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. EXECUTIVE SUMMARY

2.1 Key Insights

3. RESEARCH METHODOLOGY

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. NORTH AMERICA RADIOACTIVE TRACER MARKET - KEY INDUSTRY DYNAMICS

4.1 Key Market Drivers:
  4.1.1 Rising Prevalence of Chronic Diseases
  4.1.2 Increasing Use of Nuclear Imaging Techniques
4.2 Market Restraints
  4.2.1 Short Shelf-Life of Radioactive Tracer
  4.2.2 Availability of Substitutes to Nuclear Diagnostic Imaging Procedures
4.3 Market Opportunities
  4.3.1 New Initiatives for Radioactive Tracer R&D
4.4 Future Trends
  4.4.1 Use of Radioactive Tracer in Cancer Diagnosis
4.5 Impact Analysis:

5. RADIOACTIVE TRACER MARKET - NORTH AMERICA MARKET ANALYSIS

5.1 Radioactive Tracer Market Revenue (US$ Mn), 2022 – 2030

6. NORTH AMERICA RADIOACTIVE TRACER MARKET – REVENUE AND FORECAST TO 2030 – BY TRACER TYPES

6.1 Overview
6.2 Radioactive Tracer Market Revenue Share, by Tracer Types 2022 & 2030 (%)
6.3 Technetium 99m and TC-97m
  6.3.1 Overview
  6.3.2 Technetium 99m and TC-97m: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Iodine
  6.4.1 Overview
  6.4.2 Iodine 131: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Iron
  6.5.1 Overview
  6.5.2 Iron 59: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.6 Lutetium-
  6.6.1 Overview
  6.6.2 Lutetium- 171: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.7 RB82 and ammonia N-13
  6.7.1 Overview
  6.7.2 RB82 and ammonia N-13: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.8 Scandium
  6.8.1 Overview
  6.8.2 Scandium 46: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.9 Seaborgium-269
  6.9.1 Overview
  6.9.2 Seaborgium-269: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.10 Hassium -269
  6.10.1 Overview
  6.10.2 Hassium -269: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.11 Gallium Citrate GA
  6.11.1 Overview
  6.11.2 Gallium Citrate GA 67: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.12 PSMA GA68
  6.12.1 Overview
  6.12.2 PSMA GA68: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.13 FDDNP (F-18) and FDOPA (f-18)
  6.13.1 Overview
  6.13.2 FDDNP (F-18) and FDOPA (f-18): Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.14 Phosphorus 32 and Chromium -51
  6.14.1 Overview
  6.14.2 Phosphorus 32 and Chromium -51: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.15 Thallium-201
  6.15.1 Overview
  6.15.2 Thallium-201: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.16 F-18 FDG
  6.16.1 Overview
  6.16.2 F-18 FDG: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.17 F-18 FAPI
  6.17.1 Overview
  6.17.2 F-18 FAPI: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.18 GA 68 FAPI
  6.18.1 Overview
  6.18.2 GA 68 FAPI: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.19 F-18 PSMA
  6.19.1 Overview
  6.19.2 F-18 PSMA: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.20 DOTATOC/DOTANOC/DOTATATE Ga
  6.20.1 Overview
  6.20.2 DOTATOC/DOTANOC/DOTATATE Ga 68: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
6.21 Others
  6.21.1 Overview
  6.21.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)

7. NORTH AMERICA RADIOACTIVE TRACER MARKET – REVENUE AND FORECAST TO 2030 – BY TEST TYPE

7.1 Overview
7.2 Radioactive Tracer Market Revenue Share, by Test Type 2022 & 2030 (%)
7.3 PET
  7.3.1 Overview
  7.3.2 PET: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
7.4 SPECT
  7.4.1 Overview
  7.4.2 SPECT: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Others
  7.5.1 Overview
  7.5.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)

8. NORTH AMERICA RADIOACTIVE TRACER MARKET – REVENUE AND FORECAST TO 2030 – BY APPLICATION.

8.1 Overview
8.2 Radioactive Tracer Market Revenue Share, by Application 2022 & 2030 (%)
8.3 Oncology
  8.3.1 Overview
  8.3.2 Oncology: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.4 Pulmonary
  8.4.1 Overview
  8.4.2 Pulmonary: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.5 Neurology
  8.5.1 Overview
  8.5.2 Neurology: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.6 Cardiology
  8.6.1 Overview
  8.6.2 Cardiology: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
8.7 Others
  8.7.1 Overview
  8.7.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)

9. NORTH AMERICA RADIOACTIVE TRACER MARKET – REVENUE AND FORECAST TO 2030 – BY END USER

9.1 Overview
9.2 Radioactive Tracer Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospitals and Clinics
  9.3.1 Overview
  9.3.2 Hospitals and Clinics: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Diagnostic Centers
  9.4.1 Overview
  9.4.2 Diagnostic Centers: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9.5 Academic and Research Institutes
  9.5.1 Overview
  9.5.2 Academic and Research Institutes: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)
9.6 Others
  9.6.1 Overview
  9.6.2 Others: Radioactive Tracer Market – Revenue and Forecast to 2030 (US$ Million)

10. NORTH AMERICA RADIOACTIVE TRACER MARKET - COUNTRY ANALYSIS

10.1 North America Radioactive Tracer Market, Revenue and Forecast To 2030
  10.1.1 Overview
  10.1.2 North America Radioactive Tracer Market, by Country
    10.1.2.1 US
      10.1.2.1.1 Overview
      10.1.2.1.2 US Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
      10.1.2.1.3 US Radioactive Tracer Market, by Tracer Types
      10.1.2.1.4 US Radioactive Tracer Market, by Test Type
      10.1.2.1.5 US Radioactive Tracer Market, by Application
      10.1.2.1.6 US Radioactive Tracer Market, by End-User
    10.1.2.2 Canada
      10.1.2.2.1 Overview
      10.1.2.2.2 Canada Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
      10.1.2.2.3 Canada Radioactive Tracer Market, by Tracer Types
      10.1.2.2.4 Canada Radioactive Tracer Market, by Test Type
      10.1.2.2.5 Canada Radioactive Tracer Market, by Application
      10.1.2.2.6 Canada Radioactive Tracer Market, by End-User
    10.1.2.3 Mexico
      10.1.2.3.1 Overview
      10.1.2.3.2 Mexico Radioactive Tracer Market Revenue and Forecast to 2030 (US$ Mn)
      10.1.2.3.3 Mexico Radioactive Tracer Market, by Tracer Types
      10.1.2.3.4 Mexico Radioactive Tracer Market, by Test Type
      10.1.2.3.5 Mexico Radioactive Tracer Market, by Application
      10.1.2.3.6 Mexico Radioactive Tracer Market, by End-User

11. RADIOACTIVE TRACER MARKET INDUSTRY LANDSCAPE

11.1 Overview
11.2 Organic Developments
  11.2.1 Overview
11.3 Inorganic Developments
  11.3.1 Overview

12. RADIOACTIVE TRACER MARKET, KEY COMPANY PROFILES

12.1 Rotem Industries Ltd
  12.1.1 Key Facts
  12.1.2 Business Description
  12.1.3 Products and Services
  12.1.4 Financial Overview
  12.1.5 SWOT Analysis
  12.1.6 Key Developments
12.2 Invicro LLC
  12.2.1 Key Facts
  12.2.2 Business Description
  12.2.3 Products and Services
  12.2.4 Financial Overview
  12.2.5 SWOT Analysis
  12.2.6 Key Developments
12.3 Cardinal Health Inc
  12.3.1 Key Facts
  12.3.2 Business Description
  12.3.3 Products and Services
  12.3.4 Financial Overview
  12.3.5 SWOT Analysis
  12.3.6 Key Developments
12.4 Newcastle University
  12.4.1 Key Facts
  12.4.2 Business Description
  12.4.3 Products and Services
  12.4.4 Financial Overview
  12.4.5 SWOT Analysis
  12.4.6 Key Developments
12.5 Novartis AG
  12.5.1 Key Facts
  12.5.2 Business Description
  12.5.3 Products and Services
  12.5.4 Financial Overview
  12.5.5 SWOT Analysis
  12.5.6 Key Developments
12.6 Curium
  12.6.1 Key Facts
  12.6.2 Business Description
  12.6.3 Products and Services
  12.6.4 Financial Overview
  12.6.5 SWOT Analysis
  12.6.6 Key Developments
12.7 Blue Earth Diagnostics Limited
  12.7.1 Key Facts
  12.7.2 Business Description
  12.7.3 Products and Services
  12.7.4 Financial Overview
  12.7.5 SWOT Analysis
  12.7.6 Key Developments
12.8 General Electric Co
  12.8.1 Key Facts
  12.8.2 Business Description
  12.8.3 Products and Services
  12.8.4 Financial Overview
  12.8.5 SWOT Analysis
  12.8.6 Key Developments
12.9 IBA Radiopharma Solutions
  12.9.1 Key Facts
  12.9.2 Business Description
  12.9.3 Products and Services
  12.9.4 Financial Overview
  12.9.5 SWOT Analysis
  12.9.6 Key Developments

13. APPENDIX

13.1 About Us
13.2 Glossary of Terms


More Publications